Bioindustry

Where are we today in
terms of our bioindustry dreams for tomorrow?

The bioindustry is expected to develop steadily to counter global social issues, such as the increased population, aging society, resource depletion, and climate changes. In anticipation of explosive growth, hectic movement can be seen across many sectors of society. Let’s examine the future roadmaps for the bioindustry, as envisioned by the government, businesses, and the IFEZ.

Government | bioindustry innovation TF

 

On January 15, 2020, the Ministry of Economy and Finance created a cross-departmental bioindustry innovation TF (taskforce) team and announced policy directions and core tasks for the bioindustry. The TF team is participated in by 10 government ministries and 10 research institutions. The basic directions of the five strategies and 10 core tasks revolve around a ‘paradigm shift.’ Though the bioindustry has formerly been discussed through health and medical approaches, this will be extended to cover resources and the environment, while supply-oriented ecosystems will be expanded to the demand market. In addition, the bioindustry will extend private-level innovation, as desired by the business market.
The TF team has defined the bioindustry as a technology-intensive industry where R&D winners monopolize the market and as an industry generating economic effects in R&D processes. It is also characterized as an industry essentiating integration with other fields and a regulated industry directly connected with life. As a result, it is assessed to require challenging and adventurous research, the commercialization of innovative technology, and expanded acceptability of new businesses. Specific measures under the 10 core tasks will be consecutively announced before the end of June.

5 Strategic Fields and 10 Core Tasks

Five Strategic Fields and 10 Core Tasks to Pursue

 

Five Implemental Strategies 10 Core Tasks
R&D 1. Innovation in R&D for Reinforcement
of Global Competitiveness
· Advancement of life science research resources
· Securing common generic technology and
future core technology for each field
1. Building Big Data infrastructure for bio research resources
2. Securing promising technology as a future source of bio-related added value
Human Resources 2. Focused Fostering of Professional
Bio Human Resources
· Fostering professional human resources in medicine and bioindustry
· Fostering high-tech core human resources in bioindustry
3. Fostering excellent human resources in bioindustry
Regulations·Systems 3. Advancement of Regulations and Systems for Accelerated Market Growth
· Improvement of biohealth-related regulations
· Adjustment of financial system in bioindustry
4. Generation of reasonable regulational environments in biohealth
5. Adjustment of financial systems in bioindustry
Ecosystem 4. Support for Creation of Bio Ecosystems and
Expanding Overseas
· Reinforcement of R&D to support commercialization
· Activation of open innovation
· Support for bio business startups and exports
· Effectuation of Bio Cluster
6. Support for building up the foundations of bioindustry and expanding overseas
7. Fostering a local base through readjustment of Bio Cluster
Commercialization 5. Support for Commercializing Bio-based Technological Integration
· Fostering biotechnology-based new industries
· Exploring promising products and future business models
8. Reinforcement of global competitiveness of K-Beauty
9. Fostering and activating green-bio integrative new industries
10. Creation of initial market for White Bio

Five Strategic Fields and 10 Core Tasks to Pursue

 

* Five Implemental Strategies

R&D

1. Innovation in R&D for Reinforcement of Global Competitiveness
· Advancement of life science research resources
· Securing common generic technology and future core technology for each field

Human Resources

2. Focused Fostering of Professional Bio Human Resources
· Fostering professional human resources in medicine and bioindustry
· Fostering high-tech core human resources in bioindustry

Regulations·Systems

3. Advancement of Regulations and Systems for Accelerated Market Growth
· Improvement of biohealth-related regulations
· Adjustment of financial system in bioindustry

Ecosystem

4. Support for Creation of Bio Ecosystems and Expanding Overseas
· Reinforcement of R&D to support commercialization
· Activation of open innovation
· Support for bio business startups and exports
· Effectuation of Bio Cluster

Commercialization

5. Support for Commercializing Bio-based Technological Integration
· Fostering biotechnology-based new industries
· Exploring promising products and future business models

 

* 10 Core Tasks

R&D

1. Building Big Data infrastructure for bio research resources
2. Securing promising technology as a future source of bio-related added value

Human Resources

3. Fostering excellent human resources in bioindustry

Regulations·Systems

4. Generation of reasonable regulational environments in biohealth
5. Adjustment of financial systems in bioindustry

Ecosystem

6. Support for building up the foundations of bioindustry and expanding overseas
7. Fostering a local base through readjustment of Bio Cluster

Commercialization

8. Reinforcement of global competitiveness of K-Beauty
9. Fostering and activating green-bio integrative new industries
10. Creation of initial market for White Bio

R&D

Human Resources

Regulations·Systems

Ecosystem

Commercialization

Businesses | Future planning of Korea’s bio enterprise

 

Celltrion announced its 2030 vision to turn its course from being a First Mover to a Game Changer at the JP Morgan Healthcare Conference 2020, which is the worlds largest bio investment event, held on January 15. As a first mover in the global market, Celltrion leapt forward, occupying 81% of the monoclonal antibody (mAb) biosimilar market (2018). For its next stage of growth, while solidifying its stature by expanding its development, production, and distribution networks, Celltrion plans to launch its smart healthcare platform base business by 2030. It aims to accelerate its fourth industrial businesses and move toward expanding its business range to personalized medical services based on medical data and AI.
At the same conference, Samsung BioLogics shared its expectations for its medical contract manufacturing organization (CMO) products to increase up to 47 in number, and for its factory operational rate to reach maximum output in 2022. Samsung BioLogics will construct its fourth factory in 2020 at its reserved site in Songdo. It also plans to explore additional sites in Songdo. Moreover, the company plans on establishing an R&D institute in San Francisco in line with expanded overseas markets for its fast-growing contract development organization (CDO) business.

IFEZ | Literally the first avenue in Korea’s bioindustry

 

In the bioindustry, the IFEZ is definitely at the forefront. Not to mention pharmaceutical manufacturers, businesses specializing in process support and medical equipment, boasting secured foreign investment, along with research institutes, are forming the Bio Cluster. With production capacity for biopharmaceutical products at 560,000 liters, Songdo has taken the worlds top spot for a single city.
In 2019, the IFEZ announced its plan to expand the Bio Cluster from the originally designated Zones 4, 5, and 7 of Songdo to include Zone 11 in its efforts to maintain its positioning as Koreas Mecca in the next-generation bioindustry. In the expanded Bio Cluster, the target industrial fields will include medical equipment and digital healthcare, serving as an outpost for the next-generation bioindustry. Discussions are already underway to build related infrastructure and platforms needed in support. Boasting the highest status in production and exports, Songdo Bio Cluster is expected to rise as the worlds greatest high-tech ecosystem in the next-generation bioindustry, with the help and support of alleviated regulations preceded in accordance with the movements of governments and businesses, along with technological integration in its mature stage, leading to the development of new business models.

CEO of Celltrion, speaking at the JP Morgan Healthcare Conference 2020.

Present status of the bioindustry in Songdo

Bio Cluster Area (2019) (With an additional 990,000 m2 in Zone 11)

910,000m²

Largest global production of biopharmaceutical products (2017)
(San Francisco 440,000 ℓ, Singapore 270,000 ℓ, Ireland 230,000 ℓ)

560,000ℓ

Ratio of Korean pharmaceutical product exports: Incheon (2016)

41.5%

Licensed Korean biosimilar products (2017) (Samsung Bioepis 4, Celltrion 3),
The world’s first licensed antibody biosimilar product (Remsima) secured.

7out of10

Classification and integration patterns of the bioindustry

Red Bio
Healthcare and Medical care

Green Bio
Food and Resources

White Bio
Energy and Chemistry

Production

· Biopharmaceuticals
· Biomedical equipment

· Personalized functional food
· Medicine for animals and plants
· Seeds, microorganisms, enzymes

· Biofuels
· Cell analysis and cultivating devices
· Biochemicals

Services

· Healthcare
· Bio prescriptions and analysis

· Smart agricultural services

· Bio process

Source cross-departmental bioindustry innovation TF

Leave a Reply